Omada Health (NASDAQ:OMDA) Announces Quarterly Earnings Results

Omada Health (NASDAQ:OMDA) announced its quarterly earnings data on Thursday. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.08, FiscalAI reports. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The firm had revenue of $91.31 million for the quarter.

Here are the key takeaways from Omada Health’s conference call:

• Positive Sentiment: Omada reported record Q3 revenue of $91 million, up 34% year over year, and adjusted EBITDA of $12 million. It raised 2026 guidance to $344–$346 million in revenue and $32–$34 million in adjusted EBITDA.
• Positive Sentiment: Total members reached 1.134 million, up 36% year over year, while average program tenure rose to about two years and four months. Management said the stronger mix of diabetes and hypertension programs and lower cost to serve helped drive gross margin expansion and profitability.
• Positive Sentiment: Omada cited broader distribution through its PBM relationships and an HCSC agreement that could add an estimated 1.5 million covered lives across three states in 2027. The company said the fully insured benefit arrangement enables eligible members to enroll directly when it launches.
• Negative Sentiment: Management expects Q4 revenue below Q3 levels and a slight sequential decline in total members, reflecting typical seasonality and fewer new enrollments. The selling season has also extended into Q4 as employers take longer to weigh GLP-1 coverage and rising healthcare costs, leaving 2027 enrollment visibility unsettled.

Omada Health Stock Performance

NASDAQ:OMDA traded down $0.48 during trading on Thursday, reaching $18.95. The company’s stock had a trading volume of 1,862,389 shares, compared to its average volume of 1,008,486. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 242.88 and a beta of 2.13. Omada Health has a 12 month low of $10.28 and a 12 month high of $25.45. The firm has a 50 day moving average of $20.33 and a 200-day moving average of $17.74.

Insider Buying and Selling

In related news, President Wei-Li Shao sold 8,866 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.02, for a total transaction of $221,827.32. Following the completion of the transaction, the president owned 307,372 shares in the company, valued at approximately $7,690,447.44. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Steven Cook sold 15,235 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $25.03, for a total transaction of $381,332.05. Following the sale, the chief financial officer owned 187,209 shares of the company’s stock, valued at $4,685,841.27. This trade represents a 7.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 114,698 shares of company stock valued at $2,651,143. 6.38% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Omada Health during the 3rd quarter worth approximately $70,000. Sterling Capital Management LLC grew its holdings in Omada Health by 1,161.6% during the third quarter. Sterling Capital Management LLC now owns 1,577 shares of the company’s stock valued at $33,000 after purchasing an additional 1,452 shares during the period. Robeco Institutional Asset Management B.V. bought a new position in Omada Health during the third quarter valued at $1,100,000. Counterpoint Mutual Funds LLC bought a new position in Omada Health during the third quarter valued at $595,000. Finally, State of Alaska Department of Revenue purchased a new stake in Omada Health in the third quarter worth $59,000.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on OMDA. Robert W. Baird upped their price target on Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Citigroup reissued an “outperform” rating on shares of Omada Health in a research note on Friday, August 14th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of Omada Health in a report on Friday, September 11th. BTIG Research reaffirmed a “buy” rating and set a $35.00 target price on shares of Omada Health in a research report on Friday, September 11th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $24.00 target price on shares of Omada Health in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Omada Health currently has a consensus rating of “Moderate Buy” and an average price target of $26.42.

About Omada Health

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.